EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic value of P63 expression in stage IV B -non-Hodgkin’s lymphoma: an original research study

Samia Farag ELbelbesy, Magda Mohammed Sultan, Maha Mohamed Elgammal, Mona Nagy Elwany, Mariam Ahmed Emam, Sarah Medhat Nawar

The Egyptian Journal of Haematology · 2026-01 · 51 (1) · 38-47

DOI: 10.4103/ejh.ejh_158_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Egyptian Journal of Haematology, online erschienen am 26.03.2026. Verfasst von Samia Farag ELbelbesy und 5 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-Hodgkin lymphoma is a heterogeneous group of lymphoid tissue malignant neoplasms. B-cell lymphomas can arise at any step of normal B-cell differentiation. Each subtype possesses a unique immunophenotypic pattern, clinical behavior, and prognosis. Tumor protein p63 (TP63), a member of the p53 family, has been implicated in cancer, including hematological malignancies. This work aims to evaluate the level of p63 expression in indolent and aggressive forms of B-NHL and explore its relation to disease characteristics and response to treatment.

Methods

This study was conducted on 40 non-Hodgkin lymphoma patients and 20 healthy controls. However, non-Hodgkin lymphoma patients were divided into two groups: 20 patients with indolent B-NHL, 20 patients with aggressive B-NHL. P63 was detected by immunohistochemistry (IHC) on bone marrow biopsy specimens. Using a Ready-to-use rabbit monoclonal antibody IgG against a synthetic peptide of human p63.

Results

We defined P63 as positive when ≥1% of lymphocytes showed staining. A ROC curve was adopted to discriminate responder patients from non-responders, P63 expression cut off ≤10 with a sensitivity of 86.2% and a specificity of 90.9%. The relationship between P63 and different prognostic and therapeutic parameters was examined. Time-to-event endpoints were estimated according to the Kaplan-Meier method. Moreover, multivariate analyses were conducted.

Conclusion

The data from our study suggest that p63 expression in bone marrow biopsies of B-NHL patients could serve as a prognostic marker with potential predictive power for treatment response, particularly in aggressive cases. Visual abstract as in Fig. 1.

Zitieren

APA

ELbelbesy, S. F., Sultan, M. M., Elgammal, M. M., Elwany, M. N., Emam, M. A., & Nawar, S. M. (2026). Prognostic value of P63 expression in stage IV B -non-Hodgkin’s lymphoma: an original research study. The Egyptian Journal of Haematology, 51(1), 38-47. https://doi.org/10.4103/ejh.ejh_158_25

Vancouver

ELbelbesy SF, Sultan MM, Elgammal MM, Elwany MN, Emam MA, Nawar SM. Prognostic value of P63 expression in stage IV B -non-Hodgkin’s lymphoma: an original research study. The Egyptian Journal of Haematology. 2026;51(1):38-47. doi:10.4103/ejh.ejh_158_25

BibTeX
@article{ELbelbesy2026,
  author = {ELbelbesy, Samia Farag and Sultan, Magda Mohammed and Elgammal, Maha Mohamed and Elwany, Mona Nagy and Emam, Mariam Ahmed and Nawar, Sarah Medhat},
  title = {Prognostic value of P63 expression in stage IV B -non-Hodgkin’s lymphoma: an original research study},
  journal = {The Egyptian Journal of Haematology},
  year = {2026},
  volume = {51},
  number = {1},
  pages = {38--47},
  doi = {10.4103/ejh.ejh_158_25}
}
Kostenlos starten →